Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV | XLV Price Prediction) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital.
Pure Healthcare Exposure With Mega-Cap Anchors
XLV functions as a single-sector bet on American healthcare, holding 60 companies across pharmaceuticals, medical devices, and healthcare services. Nearly all capital—99.4% of the portfolio—stays within healthcare, creating pure sector exposure without dilution from other industries.
The fund’s massive $41 billion asset base enables institutional-grade pricing through an 0.08% expense ratio, making it one of the most cost-efficient healthcare vehicles available. Its modest 1.62% dividend yield signals a growth orientation rather than income generation, as the fund prioritizes capital appreciation from innovation and market expansion.
The fund’s return engine relies on the profitability and innovation of its underlying companies. Pharmaceutical giants generate cash through drug sales and patent protection. Medical device makers benefit from procedure volumes and technological advancement. Healthcare insurers and services companies capture margin from managing patient care.
Top holdings reveal the fund’s bet on established leaders, with Eli Lilly (NYSE:LLY) commanding 14.45% of the portfolio, driven by blockbuster obesity and diabetes treatments that generated $19.29 billion in Q4 2025 revenue. Johnson & Johnson (NYSE:JNJ) follows at 10.19%, with shares surging 59.54% over the past year. The top three holdings alone represent nearly one-third of fund assets.
Performance Against the Market Benchmark
XLV delivered single-digit returns over the past year at 9.59%, trailing the broader S&P 500 (NYSEARCA:SPY) by a modest margin. The gap widens over longer periods—healthcare’s five-year performance of 45.58% lagged the S&P 500’s 73.63% advance by nearly 30 percentage points, reflecting the sector’s defensive nature during growth-favoring environments.
Concentration Risk and Defensive Limitations
Sector concentration eliminates diversification benefits—when healthcare underperforms, there’s no buffer from technology or financial exposure. Mega-cap concentration creates single-stock risk, as demonstrated by Eli Lilly’s recent 3.07% year-to-date decline and UnitedHealth (NYSE:UNH) plunging 43.43% over the past year.
Healthcare’s defensive reputation doesn’t guarantee outperformance. The sector’s 1.6% quarterly growth trails faster-growing industries, limiting upside potential during bull markets when investors favor aggressive growth sectors over stability.
XLV works best as a tactical allocation for investors seeking healthcare exposure without individual stock selection, accepting sector concentration and potential underperformance during risk-on markets in exchange for defensive positioning during downturns.
Top Gaining Stocks
Top Losing Stocks